Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer

详细信息    查看全文

• 作者：Wu-ping Wang¹ ; ^{wwp_9@163.com" class="auth_mail" title="E-mail the corresponding author} ; Xiao-long Yan¹ ; ^{yanxiaolong@fmmu.edu.cn" class="auth_mail" title="E-mail the corresponding author} ; Wei-Miao Li¹ ; ^{liweimiao6229@hotmail.com" class="auth_mail" title="E-mail the corresponding author} ; Yun-feng Ni¹ ; ^{niyunfng@fmmu.edu.cn" class="auth_mail" title="E-mail the corresponding author} ; Jin-bo Zhao ^{zhaojinbo@aliyun.com" class="auth_mail" title="E-mail the corresponding author} ; Qiang Lu ^{luqianglu@126.com" class="auth_mail" title="E-mail the corresponding author} ; Xue-jiao Wang ^{snow-siren@163.com" class="auth_mail" title="E-mail the corresponding author} ; Ying Sun ^{suny_an1314@163.com" class="auth_mail" title="E-mail the corresponding author} ; Peng Chen ^{13402988668@163.com" class="auth_mail" title="E-mail the corresponding author} ; Bing-yang Yan ^{yan533221@163.com" class="auth_mail" title="E-mail the corresponding author} ; Yuanbo Cui ^{sqsf156@163.com" class="auth_mail" title="E-mail the corresponding author} ; Zhi-Pei Zhang ; ^{zzpzyy@fmmu.edu.cn" class="auth_mail" title="E-mail the corresponding author} ; Xiao-Fei Li ; ^{lxfchest@fmmu.edu.cn" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Gankyrin ; Oncoprotein ; Lung cancer ; NSCLC ; Survival ; Prognosis ; Immunohistochemistry
• 刊名：Pathology - Research and Practice
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：211
• 期：12
• 页码：939-947
• 全文大小：4738 K

文摘

The expression of Gankyrin, a liver cancer-related oncoprotein, has been observed in several human malignancies including non-small cell lung cancer (NSCLC). However, the clinic relevance of Gankyrin expression in NSCLC remains unclear.

Methods

Gankyrin expression was assessed using immunohistochemical (IHC) methods in 166 paired paraffin-embedded NSCLC specimens and adjacent normal tissues. Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and Western blotting were employed to measure the expression of Gankyrin in 24 paired fresh NSCLC specimens and the corresponding normal tissues. The association of Gankyrin expression with clinicopathological parameters was also evaluated. Kaplan–Meier survival analysis and Cox proportional hazards models were used to estimate the effect of Gankyrin expression on survival.

Results

Data showed that Gankyrin was expressed in 78.3% (130/166) and 28.9% (48/166) of cancer lesions and corresponding adjacent normal tissue, respectively. And the Gankyrin overexpression in tumor tissue occurred in 53.6% (89/166) of patients, while overexpression of Gankyrin in normal tissue occurred only in 4.8% (8/166) of patients (P < 0.001). Semi-quantitative RT-PCR and Western blotting showed that NSCLC specimens had increased Gankyrin mRNA and protein expression compared to the corresponding normal tissues. Out of all the clinicopathological factors analyzed, Gankyrin overexpression was significantly correlated with lymphatic metastasis (P < 0.001) and p-TNM stage (P < 0.001). Gankyrin-overexpressed NSCLC patients had a significantly shorter survival time (P < 0.001, Log-rank test), and the prognostic significance of Gankyrin overexpression was apparent in both squamous cell carcinoma patients (P = 0.028) and adenocarcinoma patients (P < 0.001). Multivariate analysis indicated that Gankyrin overexpression may be an independent prognostic factor in NSCLC (hazard ratio [HR], 1.51; P = 0.041).

Conclusion

Our results indicate that Gankyrin overexpression is of clinical significance and can serve as a prognostic biomarker in NSCLC.